Valence8 Us LP Keros Therapeutics, Inc. Transaction History
Valence8 Us LP
- $241 Billion
- Q3 2024
A detailed history of Valence8 Us LP transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Valence8 Us LP holds 8,025 shares of KROS stock, worth $454,375. This represents 0.19% of its overall portfolio holdings.
Number of Shares
8,025Holding current value
$454,375% of portfolio
0.19%Shares
1 transactions
Others Institutions Holding KROS
# of Institutions
174Shares Held
30.3MCall Options Held
76.8KPut Options Held
9K-
Black Rock Inc. New York, NY2.51MShares$142 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.9MShares$107 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.86MShares$105 Million0.0% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.52MShares$86.3 Million7.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.51MShares$85.8 Million0.01% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $1.46B
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...